Impact of cholesterol on ABC and SLC transporters expression and function and its role in disposition variability to lipid-lowering drugs

Pharmacogenomics

Volumn 10, Issue 6, 2009, Pages 1007-1016

  Rodrigues, Alice Cristina ^a   Hirata, Mario Hiroyuki ^a   Hirata, Rosario Dominguez Crespo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

ABC transporters; Cholesterol; LDL; Low density lipoprotein; SLC transporters

Indexed keywords

ABC TRANSPORTER; AMPHOTERICIN B; ATORVASTATIN; BREAST CANCER RESISTANCE PROTEIN; CYCLOSPORIN A; EZETIMIBE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEMBRANE PROTEIN; MEVINOLIN; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 2; PITAVASTATIN; PREGNANE X RECEPTOR; PROTEIN ABCC2; PROTEIN SLCO2B1; RIFAMPICIN; TALINOLOL; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG TRANSPORT; GENE ACTIVITY; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; HOMEOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; MAXIMUM PLASMA CONCENTRATION; MYOPATHY; NEPHROTOXICITY; NONHUMAN; REGULATORY MECHANISM; SIDE EFFECT; UPREGULATION;

ANTILIPEMIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CHOLESTEROL; GENE EXPRESSION; HUMANS; MEMBRANE TRANSPORT PROTEINS;

EID: 69049098314     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.18     Document Type: Article

References (47)

1. Bogman K, Peyer AK, Török M, Küsters E, Drewe J; HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br. J. Pharmacol, 132(6), 1183-1192 (2001).
2. Boyd RA, Stern RH, Stewart BH et al.: Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin. Pharmacol. 40(1), 91-98 (2000).
3. Wu X, Whitfield LR, Stewart BH: Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid cotransporter. Pharm. Res. 17(2), 209-15 (2000).
4. Chen C, Mireles RJ, Campbell SD et al.: Differential interaction of 3-hydroxy-3-methylglutaryl-coA reductase inhibitors with ABCBI, ABCC2, and OATPJB1. Drug Metab. Dispos. 33(4), 537-546 (2005).
5. Ito K, Suzuki H, Horie T, Sugiyama Y: Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharm. Res. 22, 1559-1577 (2005).
6. Rodrigues AC, Curi R, Britto LR et al.: Down-regulation ofABCBI transporter by aro-vastatin in a human hepatoma cell line and in human peripheral blood mononuclear cells. Biochim. Biophys. Acta 1760 (12), 1866-1873 (2006).
7. Li HY, Appelbaum FR, Willman CL et al.: Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood 101(9), 3628-3634 (2003).
8. Connelly-Smith L, Pattinson J, Grundy M et al.: P-glycoprotein is downregulated in KGla-primitive leukemia cells by LDL cholesterol deprivation and by HMG-CoA reductase inhibitors. Exp. Hematol. 35(12), 1793-800 (2007).
9. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl Acad. Sci. USA 84(21), 7735-7738 (1987).
10. Fromm MF, Kauffmann HM, Fritz P et al.: The effect of rifampin treatment on intestinal expression of human MRP transporters. Am. J. Pathol. 157(5), 1575-1580 (2000).
11. Maliepaard M, Scheffer GL, Faneyte IF et al.: Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 61(8), 3458-3464 (2001).
12. Boyd RA, Stern RH, Stewart BH et al.: Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J. Clin. Pharmacol. 40 (1), 91-98 (2000).
13. Westphal K, Weinbrenner A, Zschiesche M et al.: Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin. Pharmacol. Ther. 68(4), 345-355 (2000).
14. Schwarz UI, Hanso H, Oertel R et al.: Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol. Clin. Pharmacol, Ther. 81(5), 669-678 (2007).
15. Giessmann T, May K, Modess C et al.: Carbamazepirie regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. Clin. Pharmacol. Ther. 76(3), 192-200 (2004).
16. Mealey KL: Therapeutic implications of the MDR-1 gene. J. Vet. Pharmacol. Ther. 27(5), 257-264 (2004).
17. Chen C, Lin J, Smolarek T, Tremaine L: P-glycoprotein has differential effects on the disposition of statin acid and lactone forms in mdrla/b knockout and wild-type mice. Drug Metab. Dispos. 35(10), 1725-1729 (2007).
18. Rebecchi IM, Rodrigues AC, Arazi SS et al.: ABCB1 and ABCC1 expression in peripheral mononuclear cells is influenced by gene polymorphisms and atorvastatin treatment. Biochem. Pharmacol. 77(1), 66-75 (2009).
19. Niemi M, Arnold KA, Backman JT et al.: Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics. Pharmacogenet. Genomics 16(11), 801-808 (2006).
20. Bernsdorf A, Giessmann T. Modess C et al.: Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects gelotyped for the ABCB1, ABCC2 and SLC61B1 polymorphisms. Br. J. Clin. Pharmacol. 61(4), 440-450 (2006).
21. Oswald S, Haenisch S, Fricke C et al.: Intestinal expression of P-glycoprotein (ABCBl), mulfidrug resistance associated prortein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. Clin. Pharmacol. Ther. 79(3), 206-217 (2006).
22. Oswald S, Westnip S, Grube M, Kroemer HK, Weitschies W, Siegmund W: Disposition and sterol-lowering effect of ezetimibe in multidrug; resistance-associated protein 2-deficient rats. J. Pharmacol. Exp. Ther. 318(3), 1293-1299 (2006).
23. Hirano M, Maeda K, Matsushima S et al.: Involvement of BCRP (ABCG2) in the biliary excretion of picavastatin. Mol. Pharmacol. 68 (3), 800-807 (2005).
24. Gsube M, Kock K, Oswald S et al.: Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin. Pharmacol. Ther. 80(6), 607-620 (2006).
25. Couvert P, Giral P, Dejager S et al.: Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. Pharmacogenomics 9(9), 1217-1227 (2008).
26. Thompson JF, Man M, Johnson K et al.: An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomic J. 5(6), 352-358 (2005).
27. Jacobson TA: Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am. J. Cardiol. 94(9), 1140-1146 (2004).
28. Neuvonen PJ, Niemi M, Backman JT: Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin. Pharmacol. Ther. 80(6), 565-581 (2006).
29. Tobert JA: Efficacy and long-term adverse effect pattern of lovastatin. Am. J. Cardiol. 62(15), 28J-34J (1988).
30. Storch CH, Ehehalt R, Haefeli WE, Weiss J: Localization of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitro. J. Pharmacol. Exp. Ther. 323(1), 257-264 (2007).
31. Telbisz A, Muller M, Ozvegy-Laczka C et al.: Membrane cholesterol selectively modulates the activity of the human ABCG2 multidrug transporter. Biochim. Biophys. Acta 1768 (11) 2698-2713 (2007).
32. Troost J, Lindenmaier H, Haefeli WE. Weiss J: Modulation of cellular cholesterol alters P-glycoprotein activity in multidrug-resistant cells. Mol. Pharmacol. 66(5), 1332-1339 (2004).
33. Rodrigues AC, Genvigir FDV, Arazi SC et al.: Alteration of the expression of efflux and uptake transporters during hypercholesterolemia. Role in variability of atorvastatin response. Presented at: 4th Biologie Prospective Santorini Conference, Santorini, Greece, September 21-23 (2008).
34. Shu Y, Liu H: Reversal of P-glycoprotein-mediated multidrug resistance by cholesterol derived from low density lipoprotein in a vinblastine-resistant human lymphoblastic leukemia cell line. Biochem. Cell Biol. 85 (5), 638-646 (2007).
35. Srorch CH, Khmm HD, Heinrich T, Haefeli WE, Weiss J: Plasma LDL cholesterol has no impact on P-glycoprotein (MDR1/ABCB1) activity in human peripheral blood mononuclear cells. Naunyn Schmiedebergs Arch. Pharmacol 376(1-2), 135-143 (2007).
36. Dias V, Ribeiro V. The expression of the solute carriers NTCP and OCT-1 is regulated by cholesterol in HepG2 cells. Fundam. Clin. Pharmacol. 21(4), 445-450 (2007).
37. Chavanet P, Joly V, Rigaud D, Bolard J, Carbon C, Yeni P: Influence of diet on experimental toxicity of amphotericin B deoxycholate. Antimicrob. Agents Chemother. 38(5), 963-968 (1994).
38. Bassissi MF, Alvinerie M, Martin PG, Perret B, Lespine A: Influence of dyslipidemia on moxidectin distribution in plasma lipoproteins and on its pharmacokinetics. Pharm. Res. 23(11), 2672-2680 (2006).
39. Gardier AM, Mathé D, Guédeney X et al.: Effects of plasma lipid levels on blood distribution and pharmacokinetics of cyclosporin A. Ther. Drug Monit. 15 (4), 274-280 (1993).
40. Ishizaki J, Ito S, Jin M: Mechanism of decrease of oral bioavailability of cyclosporin A during immunotherapy upon coadministration of amphotericin B. Biopharm. Drug Dispos. 29(4), 195-203 (2008).
41. Dussault I, Lin M, Hollister K, Wang EH, Synold TW, Forman BM: Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR. J. Biol. Chem. 276(36), 33309-33312 (2001).
42. Kast HR, Goodwin B, Tarr PT et al.: Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J. Biol. Chem. 277(4), 2908-2915 (2002).
43. Ebert B, Seidel A, Lampen A: Identification of BCRP as transporter of Benzo [a] pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists. Carcinogenesis 26 (10), 1754-1763 (2005).
44. Jigorel E, Le Vee M, Boursierr-Neyret C, Parmentier Y, Fardel O: Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab. Dispos. 34 (10), 1756-1763 (2006).
45. Oscarson M, Zanger UM, Rifki OF, Klein K, Eichelbaum M, Meyer UA: Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clin. Pharmacol. Ther. 80(5), 440-456 (2006).
46. Maeda T, Hirayama M, Higashi R, Sato M, Tamai I: Characterization of human OATP2B1 (SLCO2B1) gene promoter regulation. Pharm. Res. 23, 513-520 (2006).
47. Stedman CA, Liddle C, Coulter SA et al.: Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. Proc. Natl Acad. Sci. USA 102(6), 2063-2068 (2005).